Aaron Shinkle, MD
Interventional Pain Medicine · Prattville, ALNPI 1497989180
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 61.4% of it on its own, with 29 other manufacturers making up the rest.
Across 380 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Collegium Pharmaceutical, Inc.$950
- Boston Scientific$607
- Scilex Pharmaceuticals Inc.$222
- Amgen$211
- Arbor Pharmaceuticals, Inc.$189
- plus $1K from 24 others
What the payments were for
- Food & beverage$8,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 209 | $5,277 |
| Collegium Pharmaceutical, Inc. | 69 | $950 |
| Boston Scientific | 19 | $607 |
| Scilex Pharmaceuticals Inc. | 14 | $222 |
| Amgen | 7 | $211 |
| Arbor Pharmaceuticals, Inc. | 9 | $189 |
| Forte Bio-pharma LLC | 4 | $177 |
| Biodelivery Sciences International, Inc. | 6 | $121 |
| Nevro Corp. | 4 | $115 |
| AbbVie(2 entities) | 7 | $115 |
| Stimwave Technologies Incorporated | 2 | $72 |
| Lilly USA, LLC | 3 | $54 |
| Azurity Pharmaceuticals, Inc. | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| SPR Therapeutics, Inc | 2 | $40 |
| Pfizer | 3 | $40 |
| Vertex | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Vertos Medical, Inc. | 1 | $34 |
| USWM, LLC | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| IBSA Pharma Inc. | 1 | $17 |
| Virtus Pharmaceuticals LLC | 1 | $16 |
| Curonix LLC | 1 | $15 |
| Neuronetics, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$477
- PROCLAIM$404
- Proclaim Family of SCS IPGs$346
- ETERNA$150
- Proclaim IPG$142
- Prodigy Family of SCS IPGs$120
- Nalocet$119
- ARTISAN$118
- GENERAL PAIN MANAGEMENT$116
- AIMOVIG$107
- Proclaim DRG IPG$103
How this compares
$8,588 in reported general payments places this provider in the 65th percentile of 33 interventional pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 276 | $211,206 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 5,105 | $82,970 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 4,330 | $82,400 |
| OxycontinOxycodone Hcl | 109 | $72,774 |
| Buprenorphine | 214 | $62,212 |
| Pregabalin | 2,068 | $46,528 |
| Gabapentin | 3,870 | $46,146 |
| Xtampza ErOxycodone Myristate | 73 | $42,255 |
| RelistorMethylnaltrexone Bromide | 15 | $31,452 |
| OzempicSemaglutide | 25 | $24,225 |
| MovantikNaloxegol Oxalate | 52 | $20,935 |
| Morphine Sulfate ErMorphine Sulfate | 655 | $18,876 |
| NucyntaTapentadol Hcl | 28 | $18,416 |
| Tizanidine Hcl | 1,808 | $14,846 |
| Lidocaine | 165 | $13,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta, Nucynta Er | $950 | $282,962397 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $38 | $31,45215 claims |
| Redhill Biopharma Inc.Movantik | $14 | $20,93552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 interventional pain medicine providers in Alabama.
Other interventional pain medicine in Prattville
- Michael KendrickBirmingham$90K
- Bradley WargoMuscle Shoals$41K
- Jacob VellaMontgomery$28K
- John IronsVestavia$22K
- Richard WebbFoley$18K
- Ryan AlmeidaBirmingham$14K
- Roberto ChangHoover$13K
- Bradley KatzMontgomery$12K
- Thomas MartinHoover$11K
- David HerrickMontgomery$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.